Michelle C. Miller

Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR

Structural significance of galectin design: impairment of homodimer stability by linker insertion and partial reversion by ligand presence

SBIR Phase I: The Games and Learning Digital Distribution Platform: Increasing Access with Web-Based Content

EAGER: Measuring the Effects of Academic Climate and Social Networks on Persistence of STEM Undergraduates